Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 15 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
Barbara Deconinck, Endocrinologie-Diabetologie from Langemark-Poelkapelle, company number BE0754795008, closed financial year 2025 with a result of € 257,809 after tax. For that financial year Barbara Deconinck, Endocrinologie-Diabetologie recorded a gross margin of € 354,151 and equity of € 6,000. Compared with financial year 2024, the result moved from € 320,550 to € 257,809. The company is profitable. The buffer shrank hard: equity is 95 % below last year. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on August 31, 2026.
€ 6,000
▼ 95% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 257,809
▼ 20% vs 2024
Profit after tax over the fiscal year.
€ 41,563
▼ 57% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 378,359 paid out
More than the year’s profit went to the shareholders; reserves fell.
People and assets in 2025
€ 52,537
▲ € 48,548 vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 3,057
▼ 59% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 13,643
▲ 24% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 381,385 | € 387,331 | € 424,139 | € 354,151 | ▼ 17% |
| Profit after taxes | € 289,876 | € 293,994 | € 320,550 | € 257,809 | ▼ 20% |
| Equity | € 807,530 | € 99,994 | € 126,550 | € 6,000 | ▼ 95% |
| Total debts | € 884 | € 215,232 | € 221,646 | € 281,482 | ▲ 27% |
| Cash | € 595,968 | € 28,102 | € 97,020 | € 41,563 | ▼ 57% |
| Retained profit | € 801,530 | € 93,994 | € 120,550 | € 0 | ▼ 100% |
| Dividend | € 0 | € 1,001,530 | € 293,994 | € 378,359 | ▲ 29% |
| Bank debt | € 675 | € 0 | € 0 | € 0 | |
| Balance sheet total | € 808,414 | € 315,226 | € 348,196 | € 287,482 | ▼ 17% |
Key figures of Barbara Deconinck, Endocrinologie-Diabetologie, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Barbara Deconinck, Endocrinologie-Diabetologie?
What happened at Barbara Deconinck, Endocrinologie-Diabetologie in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 257,809 (▼ 20% vs 2024). filed late Source: NBB ↗
- New establishment in Langemark-Poelkapelle. KBO
- Start of the company according to the CBE. KBO
- Barbara Deconinck became a director. NBB
In short
From € 289,876 profit in 2022 to € 257,809 profit in 2025.
Paid € 365,500 in corporate taxes since 2022.
Best year ever: 2024, with € 320,550 profit.
Paid out € 1.7 million in dividends to the owners in total.
A new publication or filing at Barbara Deconinck, Endocrinologie-Diabetologie? We notify you, reason included.
Follow Barbara Deconinck, Endocrinologie-DiabetologieDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind Barbara Deconinck, Endocrinologie-Diabetologie is Barbara Deconinck.
Directors
According to the 2025 annual accounts
Barbara Deconinck
Director
since 2020
Establishments
Establishment units
Physical locations of this company
Nieuwe Kalsijde 5b
8920 Langemark-Poelkapelle
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0754.795.008
- VAT number
- BE 0754.795.008
- Registered office
- Nieuwe Kalsijde 5b, 8920 Langemark-Poelkapelle
- Names & denominations
- Barbara Deconinck, Endocrinologie-Diabetologie
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 24 September 2020
- Peppol
- Active · Active since 22 Dec 2025
- Activities · NACE
Activiteiten van medisch specialisten
Overige activiteiten van vrije beroepen en andere wetenschappelijke en technische activiteiten, neg
Overige gespecialiseerde wetenschappelijke en technische activiteiten